- Received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
- “We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO.
MONTREAL , Jan. 25, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO. “Redesca™ has a long and strong history of safety and efficacy with more than 8 years of proven in-market data internationally. Redesca™ will be available across Canada and Valeo intends to pursue discussions for the inclusion of Redesca on all other provincial formularies. Valeo is planning to launch Redesca™ during the first half of 2021.”
In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWHs are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.
Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/753839-valeo-pharma-s-redesca-receives-positive-recommendation-for-public-reimbursement-in-quebec/messages/2300008#message
Tags: BioSyent Inc., CSE, HLS Therapeutics, investment, Knight Therapeutics, Medexus Pharmaceuticals, pharma, pharma stocks, Redesca, small cap, small cap pharma